BibTex RIS Cite

Epidemiologic fetaures and survival outcomes of carcinoma of the corpus uteri

Year 2019, , 33 - 38, 31.12.2019
https://doi.org/10.19161/etd.669448

Abstract

Aim: To evaluate epidemiologic features and survival outcomes of 3379 patients treated with the diagnosis of carcinoma of the corpus uteri (CC) in Ege University Hospital (EUH) between 1992-2017 and compare them with the literature.
Materials and Methods: Data recorded to CANREG-4 program in EUH between 1992-2017 by EU Fight Against Cancer Research and Application Center (EUKAM) were grouped according to WHO and SEER systems. For statistical analysis, Chi-square method and general linear modeling and Kaplan-Meier analysis were performed. In Kaplan-Meier analysis, Log Rank (Mantel-Cox), Breslow (Generalized Wilcxon) and Tarone-Ware methods were used. p<0.05 was accepted as significant.
Results: Carcinoma of the corpus uteri was the most common cancer among gynecologic cancers (41.6%). It was mostly seen at the ages between 50-59. The most common histological subtypes were epithelial tumors and endometrioid carcinoma in this group. The disease is usually localized to the uterus at the time of diagnosis (70.6%). Median survival was 120 months. 5 year overall survival rate was 68.9% and 10 year overall survival rate was 66%.
Conclusion: Carcinoma of the corpus uteri is the most common gynecologic cancer. Twenty-five years data of our hospital was found similar with the literature in regard to demographic, histopathologic features and survival outcomes.

References

  • https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/2014-RAPOR._uzuuun.pdf.
  • Cancer report 2010. Ed Tuncer Am, Moore M, Qiazo YL, Yoo KY, Tijama K, Özgül N, Gültekin M. Asian pacific organization for cancer prevention (APOCP) İstanbul 2010.
  • Jemal A, S,egel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87.
  • Galaal K, Donkers H, Bryant A, Lopes AD. Laparoscopy versus laparotomy for themanagement of early stage endometrial cancer. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No.: CD006655. DOI: 10.1002/14651858.CD006655.
  • Amant F, Moerman P, Timmerman D, Limbergen EV, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505.
  • Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute.
  • Alektiar KM, McKee A, Lin O. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002; 54: 79–85.
  • Cirisano FD, Robboy SJ, Dodge RK. Epidemiopathologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999; 74: 385–94.
  • Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994; 10: 31–46.
  • Tejerizo-García A, Jiménez-López JS, Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G, Gómez JF. Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. Onco Targets Ther. 2013; 9: 1305-13.

Korpus uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri

Year 2019, , 33 - 38, 31.12.2019
https://doi.org/10.19161/etd.669448

Abstract

Amaç: Ege Üniversitesi Hastanesinde 1992-2017 arası kanser tanı ve tedavisi yapılan 3379 korpus uteri kanserinin epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçları literatürle karşılaştırmaktır.
Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan korpus uteri kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p<0.05 istatistiksel olarak anlamlı kabul edilmiştir.
Bulgular: Korpus uteri kanseri jinekolojik kanserler arasında en sık görülen kanser (%41,6) olarak saptanmıştır. En sık görüldüğü yaş grubu 50-59’dur. Histolojik alt tip olarak en sık epitelyal tümörler ve bu grupta da endometrioid karsinom görülmüştür. Daha nadir görülen mezenkimal tümörlerden en sık stromal sarkom görülürken miks tip tümörlerde miks müllerian tümör görülmektedir. Hastalık tanı anında genellikle lokalize tümördür (%70,6). Ortalama sağ kalım süresi 120 ay olarak saptanmıştır. Genel sağ kalım oranı beş yıllık %68,9 ve 10 yıllık ise %66 olarak bulunmuştur.
Sonuç: Jinekolojik kanserler arasında en sık korpus uteri kanseri görülür. Hastanemizin 25 yıllık verileri değerlendirildiğinde demografik verilerin ve histopatolojik bulguların literatür ile uyumlu olduğu, sağ kalım sürelerinin ise gelişmiş ülkeler ile benzer olduğu görülmektedir.

References

  • https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/2014-RAPOR._uzuuun.pdf.
  • Cancer report 2010. Ed Tuncer Am, Moore M, Qiazo YL, Yoo KY, Tijama K, Özgül N, Gültekin M. Asian pacific organization for cancer prevention (APOCP) İstanbul 2010.
  • Jemal A, S,egel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87.
  • Galaal K, Donkers H, Bryant A, Lopes AD. Laparoscopy versus laparotomy for themanagement of early stage endometrial cancer. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No.: CD006655. DOI: 10.1002/14651858.CD006655.
  • Amant F, Moerman P, Timmerman D, Limbergen EV, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505.
  • Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute.
  • Alektiar KM, McKee A, Lin O. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002; 54: 79–85.
  • Cirisano FD, Robboy SJ, Dodge RK. Epidemiopathologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999; 74: 385–94.
  • Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994; 10: 31–46.
  • Tejerizo-García A, Jiménez-López JS, Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G, Gómez JF. Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. Onco Targets Ther. 2013; 9: 1305-13.
There are 11 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Supplement
Authors

Levent Akman 0000-0001-9399-8049

Nuri Yıldırım 0000-0002-0605-4750

Mustafa Coşan Terek 0000-0002-0294-2857

Zeynep Özsaran 0000-0003-4362-3542

Senem Alanyalı 0000-0002-0151-0913

Ayfer Haydaroğlu 0000-0001-5709-0981

Ulus Ali Şanlı 0000-0002-0062-6105

Erdem Göker 0000-0001-6180-713X

Osman Zekioğlu 0000-0001-9728-4385

Necmettin Özdemir 0000-0001-9721-7510

Ahmet Aydın Özsaran 0000-0002-4330-0228

Publication Date December 31, 2019
Submission Date February 15, 2019
Published in Issue Year 2019

Cite

Vancouver Akman L, Yıldırım N, Terek MC, Özsaran Z, Alanyalı S, Haydaroğlu A, Şanlı UA, Göker E, Zekioğlu O, Özdemir N, Özsaran AA. Korpus uteri kanserlerinin epidemiyoloji ve sağ kalım özellikleri. ETD. 2019:33-8.

1724617243172472652917240      26515    

 26507    26508 26517265142651826513

2652026519